Grafapex: Dosage Form, Projected Sales, NCE-1 Date | Treosulfan

Grafapex

Grafapex is used with fludarabine to prepare adults and children (≥1 year) with AML or MDS for stem cell transplant. It helps replace traditional regimens, offering similar effectiveness with potentially fewer side effects

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Treosulfan
Innovator :

MEDEXUS PHARMA INC
Approval Date :

21-Jan-25
NCE-1 Date :

21-Jan-29
NCE Date :

21-Jan-30
Dosage Form :

Intravenous Powder
Strength :

1GM/VIAL and 5GM/VIAL
Therapeutic Category :

Anticancer
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

NA
2026 :

NA
2027 :

NA
2028 :

NA
2029 :

NA
2030 :

NA
2031 :

NA

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Grafapex

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?